held in mid September, Wodford will fill the room with new fund magers ! Only 45 days from now.
Oragenics’ new lead clinical candidate achieved a 100% survival rate throughout the entire study in contrast to a 33% survival rate for the vancomycin (current standard of care) positive control. There was a 0% survival rate for the placebo control group.
Both will fly much higher.
Maybe $10+ points.?
Cancer is only recently understood to be a complex of rare diseases, with hundreds of patient-specific, cancer-promoting mutated proteins, some known and many more unknown called neoepitopes. Identifying and targeting these mutated proteins is NK’s strategy to overcome the challenges of cancer in the era of genomics, transcriptomics and immuno-oncology.
NK believes neoepitopes, which are newly discovered antigens selectively expressed on the cancer cells and not on the essential normal tissue, represent large untapped targeting opportunities for immune effector cells such as NK’s activated NK cells
both going to triple digits. Buy and Hold.
To go much higher.